Daniel Lucio, MD
Internal Medicine · Gretna, LANPI 1598751919
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 388 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,788 and has fallen 72.9% since, to $756 in 2025. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$807
- AbbVie$780
- Lilly USA, LLC$737
- AstraZeneca$625
- Amgen$414
- Novo Nordisk$311
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,17699%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 53 | $807 |
| AbbVie(2 entities) | 40 | $780 |
| Lilly USA, LLC | 51 | $737 |
| AstraZeneca | 39 | $625 |
| Amgen | 18 | $414 |
| Novo Nordisk | 25 | $311 |
| Dexcom, Inc. | 14 | $298 |
| Boehringer Ingelheim | 18 | $285 |
| Merck | 22 | $218 |
| Sanofi-aventis U.S. LLC | 12 | $188 |
| Novartis | 11 | $186 |
| Pfizer | 10 | $165 |
| Abbott | 8 | $163 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $142 |
| Johnson & Johnson | 10 | $127 |
| Kowa Pharmaceuticals America, Inc. | 7 | $111 |
| Shield Therapeutics Inc | 6 | $92 |
| Ironwood Pharmaceuticals, Inc | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $72 |
| Amarin Pharma, Inc. | 4 | $60 |
| Bayer | 4 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Nevro Corp. | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Phadia US Inc. | 2 | $25 |
| Astellas Pharma US Inc | 2 | $24 |
| Ardelyx, Inc. | 1 | $22 |
| Aytu Biopharma, Inc. | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$120
How this compares
$6,211 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 114 | $149,294 |
| JardianceEmpagliflozin | 163 | $144,796 |
| OzempicSemaglutide | 126 | $131,897 |
| EliquisApixaban | 87 | $75,512 |
| FarxigaDapagliflozin Propanediol | 78 | $59,321 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $53,897 |
| TrulicityDulaglutide | 46 | $51,834 |
| LinzessLinaclotide | 76 | $46,259 |
| JanuviaSitagliptin Phosphate | 49 | $34,736 |
| XareltoRivaroxaban | 52 | $33,464 |
| RybelsusSemaglutide | 21 | $19,661 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $17,522 |
| VascepaIcosapent Ethyl | 30 | $15,761 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $12,067 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $10,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $737 | $201,129160 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $285 | $154,888175 claims |
| Novo NordiskOzempic, Rybelsus | $311 | $151,558147 claims |
| PfizerEliquis | $165 | $75,51287 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $625 | $73,048114 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $807 | $63,64677 claims |
| AbbVieLinzess, Synthroid | $780 | $48,546110 claims |
| MerckJanuvia, Janumet Xr | $218 | $41,81962 claims |
| Johnson & JohnsonXarelto | $127 | $33,46452 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $9,59619 claims |
| NovartisEntresto | $186 | $7,86512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Gretna
- Everett BrownGretna$71K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
- Rajan KhannaShreveport$54K
- Samuel StaggEunice$54K
- Bryan LebeanLafayette$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.